Diagnostic accuracy of mean platelet volume in prediction of clopidogrel resistance in patients with acute coronary syndrome

Anadolu Kardiyoloji Dergisi

Volumn 14, Issue 2, 2014, Pages 134-139

  Uzel, Hazel ^a   Özpelit, Ebru ^a   Badak, Özer ^a   Akdeniz, Bahri ^a   Bariş, Nezihi ^a   Aytemiz, Fatih ^a   Göldeli, Özhan ^a  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

Author keywords

Acute coronary syndrome; Clopidogrel resistance; Diagnostic value; Mean platelet volume; Sensitivity; Specificity

Indexed keywords

C REACTIVE PROTEIN; CLOPIDOGREL; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; ADENOSINE DIPHOSPHATE; TICLOPIDINE;

ACUTE CORONARY SYNDROME; ADULT; ARTICLE; BLOOD CLOTTING TEST; BODY MASS; COHORT ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HUMAN; LIVER FUNCTION TEST; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PREDICTION; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; THROMBOCYTE AGGREGATION; THROMBOCYTE VOLUME; WHOLE BLOOD AGGREGOMETRY; ANALOGS AND DERIVATIVES; AREA UNDER THE CURVE; DRUG EFFECTS; DRUG RESISTANCE; EVALUATION STUDY; PREDICTIVE VALUE; THROMBOCYTE;

ACUTE CORONARY SYNDROME; ADENOSINE DIPHOSPHATE; AREA UNDER CURVE; BLOOD PLATELETS; COHORT STUDIES; DRUG RESISTANCE; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; TICLOPIDINE;

EID: 84897458081     PISSN: None     EISSN: 13080032     Source Type: Journal    
DOI: 10.5152/akd.2014.4433     Document Type: Article

References (27)

1. Storey RF, Newby LJ, Heptinstall S. Effects of P2Y(1) and P2Y(12) receptor antagonists on platelet aggregation induced by different agonists in human whole blood. Platelets 2001; 12: 443-7. [CrossRef]
2. Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, et al. Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001; 358: 527-33. [CrossRef]
3. Steinhubl SR, Berger PB, Mann JT 3rd, Fry ET, DeLago A, Wilmer C, et al. Clopidogrel for the Reduction of Events During Observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial (CREDO). JAMA 2002; 288: 2411-20. [CrossRef]
4. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502.[CrossRef]
5. Sabatine MS, Cannon CP, Gibson CM, López-Sendón JL, Montalescot G, Theroux P, et al. CLARITY-TIMI 28 Investigators. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005; 352: 1179-89. [CrossRef]
6. Chen ZM, Jiang LX, Chen YP, Peto R, Collins R, Jiang LX, et al. COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) Collaborative Group. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005; 366: 1607-21. [CrossRef]
7. Güray Y, Güray Ü, Korkmaz Ş. Clopidogrel resistance. Anadolu Kardiyol Derg 2009; 9: 231-7.
8. Matetzky S, Shenkman B, Guetta V, Shechter M, Beinart R, Goldenberg I, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004; 109: 3171-5. [CrossRef]
9. Park Y, Schone N, Harris W. Mean platelet volume as an indicator of platelet activation: methodological issues. Platelets 2002; 13: 301-6. [CrossRef]
10. Martin JF, Bath PM, Burr M. Influence of platelet size on outcome after myocardial infarction. Lancet 1991; 338: 1409-11. [CrossRef]
11. Endler G, Klimesch A, Sunder-Plassmann H, Schillinger M, Exner M, Mannhalter C, et al. Mean platelet volume is an independent risk factor for myocardial infarction but not for coronary artery disease. Br J Haematol 2002; 117: 399-404. [CrossRef]
12. Cardinal DC, Flower RJ. The electronic aggregometer: a novel device for assessing platelet behavior in blood. J Pharmacol Methods 1980; 3: 135-58 [CrossRef]
13. Tôth O, Calatzis A, Penz S, Losonczy H, Siess W. Multiple electrode aggregometry: a new device to measure platelet aggregation in whole blood. Thromb Haemost 2006; 96: 781-8.
14. Kuliczkowski W, Witkowski A, Polonski L, Watala C, Filipiak K, Budaj A, et al. Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology. Eur Heart J 2009; 30: 426-35. [CrossRef]
15. Giles H, Smith RE, Martin JF. Platelet glycoprotein IIb-IIIa and size are increased in acute myocardial infarction. Eur J Clin Invest 1994;24:69-72. [CrossRef]
16. Jakubowski JA, Adler B, Thompson CB, Valeri CR, Deykin D. Influence of platelet volume on the ability of prostacyclin to inhibit platelet aggregation and the release reaction. J Lab Clin Med 1985; 105: 271-6.
17. Chu SG, Becker RC, Berger PB, Bhatt DL, Eikelboom JW, Konkle B, et al. Mean platelet volume as a predictor of cardiovascular risk: a systematic review and meta-analysis. J Thromb Haemost 2010; 8: 148-56. [CrossRef]
18. Huczek Z, Filipiak KJ, Kochman J, Michalak M, Roik M, Piatkowski R, et al. Baseline platelet size is increased in patients with acute coronary syndromes developing early stent thrombosis and predicts future residual platelet reactivity. A case-control study. Thromb Res 2010; 125: 406-12. [CrossRef]
19. Elsenberg EH, van Werkum JW, van de Wal RM, Zomer AC, Bouman HJ, Verheugt FW et al. The influence of clinical characteristics, laboratory and inflammatory markers on 'high on-treatment platelet reactivity' as measured with different platelet function tests. Thromb Haemost 2009; 102: 719-27.
20. Lippi G, Filippozzi L, Salvagno GL, Montagnana M, Franchini M, Guidi GC, et al. Increased mean platelet volume in patients with acute coronary syndromes. Arch Pathol Lab Med 2009; 133: 1441-3.
21. Düzenli MA, Özdemir K, Aygül N, Soylu A, Tokaç M. Comparison of increased aspirin dose versus combined aspirin plus clopidogrel therapy in patients with diabetes mellitus and coronary heart disease and impaired antiplatelet response to low-dose asipirin. Am J Cardiol 2008; 102: 396-400. [CrossRef]
22. Bliden KP, Dichiara J, Lawal L, Singla A, Antonino MJ, Baker BA, et al. The association of cigarette smoking with enhanced platelet inhibition by clopidogrel. J Am Coll Cardiol 2008; 52: 531-3. [CrossRef]
23. Berger J, Bhatt D, Steinhubl S, Shao M, Steg PG, Montalescot G, et al. Smoking, clopidogrel, and mortality in patients with established cardiovascular disease. Circulation 2009; 120: 2337-44. [CrossRef]
24. Park KW, Park JJ, Jeon KH, Kang SH, Oh IY, Yang HM, et al. Clinical predictors of high posttreatment platelet reactivity to clopidogrel in Koreans. Cardiovasc Ther 2012; 30: 5-11. [CrossRef]
25. Kumar S, Saran RK, Puri A, Gupta N, Sethi R, Surin WR, et al. Profile and prevalence of clopidogrel resistance in patients of acute coronary syndrome. Indian Heart J 2007; 59: 152-6.
26. Ibrahim K, Hass N, Kolschmann S, Strasser RH, Braun-Dullaeus RC. Reversible clopidogrel resistance due to right ventricular myocardial infarction: risk factor of recurrent stent thrombosis? Clin Res Cardiol 2008; 97: 797-800. [CrossRef]
27. Giorgi MA, Girolamo GD, González CD. Nonresponders to clopidogrel: pharmacokinetics and interactions involved. Expert Opin Pharmacother 2010; 11: 2391-403. [CrossRef]